SABCS 2022 | SABCS 2022 highlights

Adam Brufsky, MD, PhD, University of Pittsburgh, Pittsburgh, PA, shares what he is looking forward to most at the San Antonio Breast Cancer Symposium (SABCS) this year, including a trial investigating whether trastuzumab deruxtecan (T-DXd) has efficacy in the third-line setting for HER2-positive metastatic breast cancer, as well as data on (T-DXd) in the neoadjuvant setting. Additionally, data on the Phase III CAPItello-291 (NCT04305496) trial investigating a pan AKT/PTEN kinase inhibitor, capivasertib, with fulvestrant will be presented. This interview took place at the San Antonio Breast Cancer Symposium (SABCS) 2022 in San Antonio, TX.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.